APLS Stock Analysis: Buy, Sell, or Hold?
APLS - Apellis Pharmaceuticals, Inc. Common Stock
$22.58
-0.47 (-2.04%)
▼
5d:
+3.82%
30d:
-10.54%
90d:
-24.86%
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 27, 2026
24d
Get Alerted When APLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: APLS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: APLS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: APLS is currently trading at $22.58, which is considered fair relative to its 30-day fair value range of $21.35 to $25.59.
Technical Outlook: Technically, APLS is in a strong uptrend. Immediate support is located at $19.26, while resistance sits at $23.79.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $33.95 (+50.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, APLS is in a strong uptrend. Immediate support is located at $19.26, while resistance sits at $23.79.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $33.95 (+50.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$21.35 -
$25.59
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 50.3% below Wall St target ($33.95)
Fair Price Analysis
30-Day Fair Range
$21.35 -
$25.59
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$19.26
Resistance Level
$23.79
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-17.37
Wall Street Target
$33.95
(+50.3%)
Revenue Growth (YoY)
133.0%
Profit Margin
4.4%
Last updated: February 01, 2026 9:13 PM ET
Data refreshes hourly during market hours. Next update: 10:13 PM
Data refreshes hourly during market hours. Next update: 10:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is APLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Timothy Eugene Sullivan
SELL
10000 shares
2025-10-21
David O Watson
SELL
5000 shares
2025-10-16
A. Sinclair Dunlop
SELL
31092 shares
2025-10-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$84 | 55 HOLD |
